Format

Send to

Choose Destination
Cardiology. 2010;116(2):89-97. doi: 10.1159/000315394. Epub 2010 Jun 5.

Clarithromycin use and risk of death in patients with ischemic heart disease.

Author information

1
Department of Cardiology, Gentofte Hospital, Copenhagen, Denmark. ssa@heart.dk

Abstract

OBJECTIVES:

To examine whether treatment with clarithromycin was associated with an increased risk of death in patients with preexisting ischemic heart disease (IHD).

METHODS:

Employing nationwide registers, all patients with IHD events from 1997 to 2007 who subsequently claimed prescriptions for dual antibiotic treatment for eradication treatment were identified. The primary endpoint was all-cause mortality.

RESULTS:

The study included 214,330 individuals with IHD; 5,265 (2.5 %) of these claimed prescriptions for dual antibiotics. Compared with IHD patients not undergoing eradication therapy, no increase in the risk of all-cause mortality was demonstrated (HR 1.02; 95% CI 0.84-1.23, p = 0.87) after 5 years.

CONCLUSIONS:

The use of clarithromycin in the setting of eradication treatment for Helicobacter pylori in patients with IHD was not associated with an increased risk of death.

PMID:
20523043
DOI:
10.1159/000315394
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center